Performance Note: Potential for no output/no telemetry condition in subset of IPG and CRT-P products due to ceramic capacitor leakage pathway
Azure™ and Astra™ pacemakers, and Percepta™, Serena™ and Solara™ CRT-P
Original Date of Communication:
Medtronic has identified a rare but potentially serious failure mode in a population of Azure™ and Astra™ pacemakers, and Percepta™, Serena™ and Solara™ cardiac resynchronization therapy pacemakers (CRT-P), manufactured with a specific multilayer ceramic capacitor. These devices continue to perform within reliability projections.
While inherently very reliable, a known failure mode of these capacitors is the potential for internal cracking that can be caused by thermal-mechanical stress during manufacturing. Under rare conditions, internal cracking within a capacitor may result in the development of a leakage pathway, causing high current drain and leading to rapid battery depletion. While the issue presents as rapid battery depletion, this is not a battery performance issue.
As of April 26, 2019, three complaints out of ~266,700 devices distributed worldwide since February 2017, have been received that included a no output /no telemetry scenario resulting from rapid battery depletion. Battery depletion due to this issue can range from several days to several weeks. One of these reported events contributed to a patient death. The three confirmed failures occurred within 9 months post implant. The projected rate for this issue is 0.0028%, with the most susceptible period for a leakage pathway to develop in the capacitor being the first 12 months post implant.
Based on the low predicted rate of failure and the recent implementation of process and component enhancements, Medtronic expects few, if any, additional events to occur. Medtronic, in consultation with our Independent Physician Quality Panel, does not recommend device replacement. Physicians should continue normal patient follow-up in accordance with standard practice, and where possible, continue to utilize the low battery voltage wireless CareAlert™ (shipped ON), together with remote monitoring via CareLink™ home monitor or the MyCareLink Heart™ mobile app. Per the instructions for use, at each follow-up, verify the status of the implanted system as well as the clinical effectiveness of the device. Pay attention to any unexpected changes in remaining longevity estimates or the inability to interrogate the device and/or transmit data.
Contact Medtronic Technical Services if you have concerns on a specific patient.
Brady Technical Services |email@example.com| 800-505-4636
STATUS UPDATE – October 2019
As of October 17, 2019, there have been six additional confirmed events (for total of nine worldwide) associated with this failure mode. One of the additional confirmed events was reported as patient death.* All events have occurred within two and ten months from the initial implant. The rate of occurrence based on accelerated test data and the additional six field failures is projected to be 0.006%.
Product manufactured as of June 1, 2019, utilizes a new low voltage capacitor; product manufactured prior to June 1, 2019, continues to perform within our reliability projections as established as part of the product development process.
*Cause of death was reported as acute cerebrovascular accident, which occurred several days prior to hospital admission. Manner of death was
reported as natural; loss of pacing therapy could not be ruled out as a contributing factor.
Confirmed premature battery depletions, regardless of cause, are reported in our semi-annual Product Performance report under the confirmed “Malfunctions” section for each device model. Product Performance information can be accessed directly at: https://wwwp.medtronic.com/productperformance/